News|Articles|November 1, 2006

Pipeline Preview (November 2006)

Lisdexamfetamine (NRP104, Shire/New River Pharmaceuticals) for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD)

Approvable designations

Fast-track designations

Orphan drug designations

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Related Content